Healthcare Industry News:  ADHD 

Biopharmaceuticals Generics FDA Product Launch

 News Release - October 7, 2013

Par Pharmaceutical Begins Shipment of Generic Kapvay(R)

WOODCLIFF LAKE, N.J., Oct. 7, 2013 -- (Healthcare Sales & Marketing Network) -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for clonidine hydrochloride (HCl) 0.1 mg extended-release (ER) tablets. Clonidine HCl ER is the generic version of Concordia's KapvayĀ® and is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.

Par has begun shipping the 0.1 mg strength of the product. According to IMS Health data, annual U.S. sales of Kapvay are approximately $72 million.

Important Information About Clonidine HCl ER Tablets

Clonidine hydrochloride extended-release tablets are contraindicated in patients with a known hypersensitivity to clonidine.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.


Source: Par Pharmaceutical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.